论文部分内容阅读
目的:探讨增殖抑制基因(HSG)、血管内皮生长因子(VEGF)和增殖细胞核抗原(Ki-67)在乳腺癌组织中的表达及临床意义。方法:应用免疫组织化学方法检测唐山市工人医院60例乳腺癌标本、20例乳腺纤维腺瘤标本及20例正常乳腺组织标本中HSG、VEGF和Ki-67的表达。结果:HSG的表达与乳腺癌患者的年龄、肿瘤大小和TNM分期无关,而随着淋巴结的转移而降低(P<0.05);VEGF与乳腺癌患者的年龄及TNM分期无关,而随着肿瘤的增大及淋巴结的转移而明显增高(P<0.05);Ki-67与乳腺癌患者的TNM分期及淋巴结转移有关,随着分期的增高和淋巴结的转移,Ki-67的百分率明显升高(P<0.05)。Spearman等级相关分析显示:在乳腺癌组织中,HSG与VEGF和Ki-67的表达均呈负相关(r=-0.795,P<0.05;r=-0.811,P<0.05),VEGF和Ki-67的表达呈正相关(r=0.383,P<0.05)。结论:HSG在某种程度上可抑制VEGF及Ki-67的表达,减少乳腺癌的侵袭和转移,可见联合检测HSG、VEGF和Ki-67的表达有利于更好地判断乳腺癌的进展及预后。
Objective: To investigate the expression and clinical significance of proliferation inhibitory factor (HSG), vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (Ki-67) in breast cancer. Methods: Immunohistochemistry was used to detect the expression of HSG, VEGF and Ki-67 in 60 cases of breast cancer specimens, 20 cases of breast fibroadenoma specimens and 20 cases of normal breast tissues from Tangshan Workers’ Hospital. Results: The expression of HSG was not related to the age, tumor size and TNM stage in patients with breast cancer, but decreased with lymph node metastasis (P <0.05). The expression of HSG was not related to the age and TNM stage of patients with breast cancer, (P <0.05). Ki-67 was correlated with TNM stage and lymph node metastasis in patients with breast cancer, and the percentage of Ki-67 was significantly increased with the increase of staging and lymph node metastasis <0.05). Spearman rank correlation analysis showed that the expression of HSG was negatively correlated with the expression of VEGF and Ki-67 in breast cancer (r = -0.795, P <0.05; r = -0.811, P <0.05) (R = 0.383, P <0.05). Conclusion: HSG can inhibit the expression of VEGF and Ki-67 to a certain extent and reduce the invasion and metastasis of breast cancer. Combined detection of HSG, VEGF and Ki-67 expression is helpful to better judge the progress and prognosis of breast cancer .